SIREN : 922081328
SURGICAL IMPLANTS GROUP is a French company founded 3 years ago, specialized in the sector Gestion de fonds. Based in WERVICQ-SUD (59117), this company of category PME shows in 2024 a revenue of 3.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 |
|---|---|---|
| Revenue | 2 955 667 € | 2 785 181 € |
| Net income | -174 190 € | -1 147 335 € |
| EBITDA | 132 209 € | -196 614 € |
| Net margin | -5.9% | -41.2% |
In 2024, SURGICAL IMPLANTS GROUP achieves revenue of 3.0 M€. Vs 2023: +6%. After deducting consumption (0 €), gross margin stands at 3.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 132 k€, representing 4.5% of revenue. Positive scissor effect: EBITDA margin improves by +11.5 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -174 k€ (-5.9% of revenue), which will impact equity.
2 955 667 €
2 955 667 €
132 209 €
103 192 €
-174 190 €
4.5%
The debt ratio (= Financial debt / Equity x 100) stands at 171%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 41.1 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 44.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
171.477%
36.317%
44.887%
41.126
30.6%
In 2024, the debt ratio of SURGICAL IMPLANTS GROUP (171.48) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of SURGICAL IMPLANTS GROUP (36.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of SURGICAL IMPLANTS GROUP (41.13) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 619.52. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 3316.7x. Operating income very largely covers interest expenses: high safety margin.
619.524
3316.652
In 2024, the liquidity ratio of SURGICAL IMPLANTS GROUP (619.52) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of SURGICAL IMPLANTS GROUP (3316.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 13 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 126 days. Excellent situation: suppliers finance 113 days of the operating cycle (retail model). Overall, WCR represents 635 days of revenue, i.e. 5.2 M€ to permanently finance.
5 212 289 €
13 j
126 j
0 j
635 j
Based on 62 transactions of similar company sales
in 2024,
the value of SURGICAL IMPLANTS GROUP is estimated at
733 844 €
(range 297 881€ - 1 831 920€).
With an EBITDA of 132 209€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.30x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SURGICAL IMPLANTS GROUP with other companies in the same sector:
The revenue of SURGICAL IMPLANTS GROUP in 2024 is 3.0 M€.
SURGICAL IMPLANTS GROUP recorded a net loss in 2024.
The headquarters of SURGICAL IMPLANTS GROUP is located in WERVICQ-SUD (59117), in the department Nord.
The tax return of SURGICAL IMPLANTS GROUP is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SURGICAL IMPLANTS GROUP operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.